Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Quote.Descriptions.analyst-ratings.
1calculated from analyst ratings
The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by HC Wainwright & Co. on December 9, 2024. The analyst firm set a price target for $80.00 expecting BEAM to rise to within 12 months (a possible 244.68% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by HC Wainwright & Co., and Beam Therapeutics reiterated their buy rating.
The last upgrade for Beam Therapeutics Inc happened on November 6, 2024 when Leerink Partners raised their price target to $39. Leerink Partners previously had a market perform for Beam Therapeutics Inc.
The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on December 9, 2024 so you should expect the next rating to be made available sometime around December 9, 2025.
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a reiterated with a price target of $80.00 to $80.00. The current price Beam Therapeutics (BEAM) is trading at is $23.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.